BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30807218)

  • 1. A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores.
    Barkovich EJ; Shankar PR; Westphalen AC
    AJR Am J Roentgenol; 2019 Apr; 212(4):847-854. PubMed ID: 30807218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
    AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
    Woo S; Suh CH; Kim SY; Cho JY; Kim SH
    Eur Urol; 2017 Aug; 72(2):177-188. PubMed ID: 28196723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Contrast-Enhanced MRI-Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
    Abreu-Gomez J; Krishna S; Narayanasamy S; Flood TA; McInnes MDF; Schieda N
    AJR Am J Roentgenol; 2019 Oct; 213(4):836-843. PubMed ID: 31120786
    [No Abstract]   [Full Text] [Related]  

  • 10. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer.
    Matsuoka Y; Ishioka J; Tanaka H; Kimura T; Yoshida S; Saito K; Fujii Y; Kihara K
    AJR Am J Roentgenol; 2017 Aug; 209(2):W76-W84. PubMed ID: 28570124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level.
    Oerther B; Engel H; Bamberg F; Sigle A; Gratzke C; Benndorf M
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):256-263. PubMed ID: 34230616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    Purysko AS; Bittencourt LK; Bullen JA; Mostardeiro TR; Herts BR; Klein EA
    AJR Am J Roentgenol; 2017 Aug; 209(2):339-349. PubMed ID: 28570099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
    Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
    Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging.
    Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
    Biomed Res Int; 2020; 2020():2819701. PubMed ID: 32337234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.